ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Plasma Melanin-Concentrating Hormone in Childhood Obesity and Its Association with Metabolic Parameters: A Clinical Observational Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Obesity is a global public health problem associated with complex neuroendocrine dysregulation. Melanin-concentrating hormone (MCH), a hypothalamic regulator of energy balance, promotes appetite and positive energy balance and has been linked to metabolic disturbances in adults. However, its clinical relevance in childhood obesity, where neuroendocrine alterations may precede overt metabolic complications, remains insufficiently characterized. Aim: This study aimed to determine whether plasma MCH levels are associated with metabolic alterations in children and adolescents with obesity. Methods: In this clinical observational study, 283 participants were classified according to World Health Organization BMI-for-age criteria into obese and normal-weight groups. Plasma MCH concentrations were measured using a validated high-sensitivity radioimmunoassay (analytical detection limit: 0.2 fmol/mL). Anthropometric parameters, glucose-insulin homeostasis markers (glucose, insulin, C-peptide, HOMA-IR), lipid profile, thyroid hormones, and liver enzymes were assessed. Associations were analyzed using Spearman correlation after non-parametric distribution testing. Results: Plasma MCH exhibited limited and selective associations with metabolic parameters in obese children and adolescents. Modest correlations were observed within the glucose-insulin and thyroid-related domains, whereas associations with lipid profile measures were weak or inverse. These patterns suggest age-dependent neuroendocrine involvement in pediatric obesity. Conclusion: Elevated plasma MCH levels in childhood obesity are associated with selective neuroendocrine and metabolic alterations rather than overt dyslipidemia. In view of the cross-sectional design and modest effect sizes, these findings should be considered exploratory and require confirmation in longitudinal pediatric studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.